🧵 1. Novo Nordisk's weight loss drug Wegovy lowers heart attack risk by 20%, making it a potential life-saving treatment for obesity and heart disease. #business
🧵 1. Novo Nordisk's weight loss drug Wegovy lowers heart attack risk by 20%, making it a potential life-saving treatment for obesity and heart disease. #business
🧵 2. In a 5-year study, Wegovy reduced non-fatal heart attacks by 28% and showed potential to prevent diabetes by 73%. Promising results for obesity treatment.
🧵 3. Wegovy's success in lowering cardiovascular risks could expand insurance coverage and increase usage of the anti-obesity drug. A major breakthrough in the field.
🧵 4. Novo Nordisk's lead over Eli Lilly's competing drug Zepbound grows as Wegovy demonstrates positive cardiac outcomes, while Zepbound focuses solely on weight loss.
🧵 5. Insurance companies may prioritize drugs like Wegovy that reduce cardiovascular events, paving the way for more widespread adoption of these potentially life-saving treatments.
🧵 Read more at: https://www.cnbc.com/2023/11/11/weight-loss-drug-wegovy-slashes-risk-of-serious-heart-complications.html